Basiliximab treatment of severe GVHD induced by donor lymphocyte infusion with interferon‐a

Abstract

The development of acute graft‐versus‐host‐disease (GVHD) in recipients of donor lymphocyte infusion (DLI) is not rare and the complication is quite often fatal. We describe a severe skin GVHD patient who responded well to basiliximab. A 20‐year‐old male who received a hematopoietic stem cell transplantation (HSCT) at his age of eighteen. His fusion gene Aml1/Eto remained positive,so he was administered with DLI combined with interfern‐a(IFN‐a). Forty days after the therapy, he presented with severe skin rashes with multiple mucous membrane involvement. The skin and mucous lesions recovered after basiliximab treatment. So far, severe type of erythema multiforme in GVHD patients after DLI with IFN‐a injection is firstly reported here, together with a new alternative therapy.

This article is protected by copyright. All rights reserved.

http://bit.ly/2Q7D686